PorTal Access has received U.S. FDA clearance for its FLEXI-PORT family of implantable vascular access ports, marking a commercial milestone for the company’s vascular access technology.
FLEXI-PORT is a power-injectable implantable port system intended for long-term vascular access in adult and paediatric patients. The system is available in 5Fr and 6Fr configurations and can be implanted in either the chest or arm, giving clinicians more flexibility across different patient needs and procedural settings.
This is relevant as implantable vascular access ports are widely used for patients who require repeated venous access, including those receiving chemotherapy, long-term infusion therapy, parenteral nutrition or frequent blood draws. Port design can affect procedural workflow, patient comfort, access reliability and clinician preference.
PorTal Access is positioning FLEXI-PORT around procedural simplicity and patient-centred care. The company said the device was developed to address longstanding challenges in vascular access, with a design intended to support implantation, positioning and access workflows.
PorTal Access highlights this product as the only flexible port currently on the market. PorTal Access also stated that the device requires a small incision, which may be relevant for procedural efficiency, patient recovery and cosmetic considerations, particularly in oncology care where patients may need long-term implanted access.
The clearance is also important commercially because it moves the company from development into market preparation. PorTal Access said it will now advance commercialisation efforts, clinician training programmes and collaboration with healthcare systems to expand availability of FLEXI-PORT across the United States.
Clinician adoption will depend on procedural experience, training, pricing, hospital procurement, compatibility with existing vascular access workflows and evidence that the device offers practical advantages over established port systems. In vascular access, even small design changes must prove reliability, safety and usability across routine and complex patient cases.
The company also highlighted physician investor support, stating that more than 85 per cent of its funding came from physicians who place or refer patients for chemotherapy ports. This may help early clinical engagement, but broader uptake will still require evidence, distribution and institutional acceptance.
For hospitals and oncology centres, the key question will be whether FLEXI-PORT can improve port placement flexibility and patient experience without adding complexity to established workflows. Paediatric use may also require careful attention to sizing, implantation approach and long-term access management.
